<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - OXYBUTYNIN HYDROCHLORIDE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>OXYBUTYNIN HYDROCHLORIDE</h1>

        <p><a href="../drugClass/PHP34659.html">ANTIMUSCARINICS (SYSTEMIC)</a></p>

      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#nationalFunding" data-toggle="tab">National funding/access decisions</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Urinary frequency</span>,
                <span class="indication">Urinary urgency</span>,
                <span class="indication">Urinary incontinence</span>,
                <span class="indication">Neurogenic bladder instability</span>,
            </h4>
            <p class="specificity"><span class="route">By transdermal application using patches</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 5 mg 2&#8211;3 times a day, (by mouth) increased if necessary up to 5 mg 4 times a day.</li>
              <li class="dose adult"><strong>For adults elderly</strong><br/>
                Initially 2.5&#8211;3 mg twice daily, (by mouth using immediate-release medicines) increased if tolerated to 5 mg twice daily, adjusted according to response.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 5 mg once daily, (by mouth) increased in steps of 5 mg every 1 week, adjusted according to response; maximum 20 mg per day.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                Apply 1 patch twice weekly, patch is to be applied to clean, dry unbroken skin on abdomen, hip or buttock. Patch should be removed every 3-4 days and site replacement patch on a different area. The same area should be avoided for 7 days.</li>
              <li class="dose child"><strong>For children 5&#8211;11 years</strong><br/>
                Initially 2.5&#8211;3 mg twice daily, (by mouth using immediate-release medicines) increased to 5 mg 2&#8211;3 times a day.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                Initially 5 mg 2&#8211;3 times a day, (by mouth) increased if necessary up to 5 mg 4 times a day.</li>
              <li class="dose child"><strong>For children 5&#8211;17 years</strong><br/>
                Initially 5 mg once daily, (by mouth) adjusted in steps of 5 mg every 1 week, adjusted according to response; maximum 15 mg per day.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Nocturnal enuresis associated with overactive bladder</span>,
            </h4>
            <p class="specificity"><span class="route">Initially by mouth using modified-release tablets</span></p>
            <ul class="doses">
              <li class="dose child"><strong>For children 5&#8211;17 years</strong><br/>
                2.5&#8211;3 mg twice daily, increased to 5 mg 2&#8211;3 times a day, last dose to be taken before bedtime.</li>
              <li class="dose child"><strong>For children 5&#8211;17 years</strong><br/>
                Initially 5 mg once daily, (by mouth) adjusted in steps of 5 mg every 1 week, adjusted according to response; maximum 15 mg per day.</li>
            </ul>
          </section>
        </section>
        
        
            <section class="doseEquivalence">
                <h3>Dose equivalence and conversion</h3>
              <p>Patients taking immediate-release oxybutynin may be transferred to the nearest equivalent daily dose of <i>Lyrinel <tm tmtype="reg"/> XL</i>
            </p>
            </section>
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Manufacturers advise avoid unless essential&#8212;toxicity in <i>animal</i> studies.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <p>Manufacturer advises caution.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

        
            <section class="generalInformation">
              <p>Manufacturer advises caution.</p>
            </section>
      </section>


      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>uncommon:</strong> Anorexia, facial flushing,
              </p>
              <p>
                <strong>rare:</strong> Night terrors,
              </p>
              <p>
                <strong>notKnown:</strong> Cognitive impairment in adults,
              </p>
        
          <h3>Specific side effects</h3>
              <p>
                <strong>rare:</strong> application site reactions with <i>patches</i> in adults,
              </p>
        
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">transdermal</ph> use in adults</h3>
              <p>Apply patches to clean, dry, unbroken skin on abdomen, hip or buttock, remove after every 3&#8211;4 days and site replacement patch on a different area (avoid using same area for 7 days).</p>
            </section>
      </section>

      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="generalPatientAdvice">
              <h3 class="specificity">With <ph outputclass="route">transdermal</ph> use in adults</h3>
              <p>Patients or carers should be given advice on how to administer oxybutynin transdermal patches.</p>
            </section>
            <section class="patientResources">
              <h3 class="specificity">In children</h3>
                <p class="title">Medicines for Children leaflet: Oxybutynin for daytime urinary symptoms</p>
              <p>
            <xref format="html" href="http://www.medicinesforchildren.org.uk/oxybutynin-for-daytime-urinary-symptoms">www.medicinesforchildren.org.uk/oxybutynin-for-daytime-urinary-symptoms</xref>
            </p>
            </section>
      </section>

      <section class="tab-pane" id="nationalFunding">
        <h2>National funding/access decisions</h2>

      </section>


      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            <xref format="dita" href="#PHP78608" type="bookmark" namespace="/treatment-summaries/acute-porphyrias">Acute porphyrias</xref>
          </li>
        </ul>
      </section>



      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <h3 class="specificity">In children</h3>
              <p>Not licensed for use in children under 5 years.</p><p>Intravesical instillation not licensed for use in children.</p>
            </section>
      </section>

      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
              <h3 class="specificity">In adults</h3>
              <p>The need for continuing therapy for urinary incontinence should be reviewed every 4&#8211;6 weeks until symptoms stabilise, and then every 6&#8211;12 months.</p>
            </section>
            <section class="prescribingAndDispensingInformation">
              <h3 class="specificity">In children</h3>
              <p>The need for therapy for urinary indications should be reviewed soon after it has been commenced and then at regular intervals; a response usually occurs within 6 months but may take longer.</p>
            </section>
            <section class="prescribingAndDispensingInformation">
              <h3 class="specificity">In children</h3>
              <p>Intravesical instillation may be available from 'special-order' manufacturers or specialist importing companies.</p>
            </section>
      </section>









      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of OXYBUTYNIN HYDROCHLORIDE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            oral suspension,
            oral solution,
            bladder irrigation,

            <div id="PHP77041"><a href="../medicinalForm/PHP77041.html" data-target="#PHP77041" data-action="load">Tablet</a></div>
            <div id="PHP77048"><a href="../medicinalForm/PHP77048.html" data-target="#PHP77048" data-action="load">Modified-release tablet</a></div>
            <div id="PHP77063"><a href="../medicinalForm/PHP77063.html" data-target="#PHP77063" data-action="load">Oral solution</a></div>
            <div id="PHP77056"><a href="../medicinalForm/PHP77056.html" data-target="#PHP77056" data-action="load">Transdermal patch</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
